春立医疗融资融券信息显示，融资方面，当日融资买入740.78万元，融资偿还656.02万元，融资净买入 84.76万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量1.24万股，融券余额31.99万元。融资 融券余额4090.05万元。 证券之星消息，截至2026年1月27日收盘，春立医疗(688236)报收于25.8元，下跌3.04%，换手率 0.87%，成交量2.5万手，成交额6458.86万元。 1月27日的资金流向数据方面，主力资金净流出13.76万元，占总成交额0.21%，游资资金净流入263.09 万元，占总成交额4.07%，散户资金净流出249.34万元，占总成交额3.86%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451. ...

Group 1 - The core viewpoint is that innovative drugs are expected to show significant excess returns in 2025, driven by continuous BD overseas expansion, excellent clinical data, and policy support [1] - The CXO sector is anticipated to experience substantial growth due to the recovery in demand and improved investment environment in the global pharmaceutical industry [1] - The report emphasizes the importance of focusing on new technologies, particularly bispecific antibodies, small nucleic acid drugs, AI healthcare, and brain-computer interface innovations [3] Group 2 - Domestic supply and demand are relatively stable, with national health expenditure showing a year-on-year growth of 4.7% from January to November 2025, marking a positive turnaround after two years of decline [2] - The medical insurance fund's income and expenditure growth rates continue to decline, with total income of 2.63 trillion yuan (+2.9%) and expenditure of 2.11 trillion yuan (+0.5%) from January to November [2] - The report suggests that the commercialization of new drug forms is entering a critical phase, with significant clinical data supporting the application of B-cell depletion therapies in autoimmune diseases [3] Group 3 - Investment recommendations include focusing on innovative overseas expansion and new technology directions, with suggested stocks such as Mindray Medical, WuXi AppTec, and others [4] - The report highlights the potential for explosive growth in the global market for brain-computer interfaces, supported by policy incentives and technological breakthroughs [3]

近5日资金流向一览见下表： 证券之星消息，截至2026年1月26日收盘，春立医疗(688236)报收于26.61元，下跌1.11%，换手率 0.79%，成交量2.28万手，成交额6098.04万元。 1月26日的资金流向数据方面，主力资金净流出372.24万元，占总成交额6.1%，游资资金净流出24.28万 元，占总成交额0.4%，散户资金净流入396.52万元，占总成交额6.5%。 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为31 ...

Core Insights - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 21,200 shares on January 23 [1] - Over the past five trading days, there have been five days of net increases in holdings, totaling 995,300 shares [1] - In the last twenty trading days, there were eight days of net reductions, amounting to 2,141,500 shares [1] - Currently, southbound funds hold 42,367,800 shares of Chuangli Medical, representing 44.52% of the company's issued ordinary shares [1] Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow [1] - The company's products are sold in both domestic and international markets [1]

Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong performance in the orthopedic medical device sector [2] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2] - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2] - The non-recurring net profit was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2] - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2] - The quarterly net profit attributable to shareholders was 77.06 million yuan, soaring by 531.12% year-on-year [2] - The quarterly non-recurring net profit stood at 74.52 million yuan, an increase of 439.4% year-on-year [2] - The company's debt ratio is reported at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2] - The gross profit margin is noted at 67.27% [2] Market Activity - As of January 23, 2026, the stock closed at 26.91 yuan, with a 1.17% increase [1] - The turnover rate was 0.73%, with a trading volume of 21,200 hands and a transaction amount of 57.25 million yuan [1] - On January 23, the net outflow of main funds was 145,000 yuan, accounting for 0.25% of the total transaction amount [1] - Retail investors saw a net inflow of 3.0137 million yuan, representing 5.26% of the total transaction amount [1] - Over the past 90 days, 8 institutions have rated the stock, all giving a buy rating, with an average target price of 31.7 yuan [2]

Group 1 - The core viewpoint of the article highlights the recent increase in southbound capital holdings in Chunli Medical (01858.HK), with a net increase of 113,800 shares on January 22 [1] - Over the past five trading days, Chunli Medical has seen an increase in southbound capital for four days, totaling a net increase of 865,300 shares [1] - In the last twenty trading days, there were eight days of net reduction in southbound capital, amounting to a total decrease of 1,949,000 shares [1] Group 2 - As of now, southbound capital holds 42,346,600 shares of Chunli Medical, representing 44.5% of the company's total issued ordinary shares [1] - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]

Core Viewpoint - Spring Medical (688236) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The net profit excluding non-recurring items was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, soaring by 531.12% year-on-year [2]. - The quarterly net profit excluding non-recurring items was 74.52 million yuan, up 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 22, 2026, Spring Medical's stock closed at 26.6 yuan, down 0.64%, with a turnover rate of 0.72% and a trading volume of 20,700 hands, amounting to a transaction value of 55.49 million yuan [1]. - On January 22, the net outflow of main funds was 4.5364 million yuan, accounting for 8.18% of the total transaction value, while retail investors saw a net inflow of 1.1627 million yuan, representing 2.1% of the total [1]. Analyst Ratings - In the last 90 days, 8 institutions have rated Spring Medical with a "buy" recommendation, and the average target price set by these institutions is 31.7 yuan [3].

Investment Rating - The industry investment rating is "Increase Holding" [2][5] Core Insights - The recent release of the "Guidelines for the Pricing of Surgical and Treatment Auxiliary Medical Services" by the National Medical Insurance Administration aims to standardize pricing for innovative medical technologies, including surgical robots, which is expected to accelerate clinical application [4] - The guidelines introduce a tiered pricing model based on the level of participation and clinical value of surgical robots, allowing for higher fees for more advanced functionalities [4] - The establishment of a new pricing project for "Remote Surgical Assistance" facilitates the practical application of remote surgery, enhancing access to quality medical resources across regions [4] - The guidelines clarify the boundaries between consumable costs and technical service fees, promoting transparency and reducing unreasonable price increases in the industry [4] - The inclusion of medical data storage and device operation records in the pricing structure is expected to support future technological iterations and application expansions [4] Summary by Sections Industry Overview - The industry comprises 133 listed companies with a total market value of 14,628.56 billion and a circulating market value of 13,032.75 billion [2] Policy Impact - The new pricing guidelines are anticipated to break the commercialization bottleneck of surgical robots, emphasizing the need for continuous innovation among companies [4] - Companies with technological accumulation and high product maturity, such as Tianzhihang-U, Jingfeng Medical-B, and others, are expected to benefit from the inclusion of robotic-assisted surgery projects in local medical insurance directories [4]

Summary of Conference Call on Northeast Medical Health Industry Industry Overview - The conference call discusses the Northeast Medical Health industry, specifically focusing on the recent developments in surgical robotics and innovative medical technologies. Key Points and Arguments 1. **National Pricing Guidelines**: On January 20, the National Healthcare Security Administration (NHSA) released the "Guidelines for the Establishment of Pricing Projects for Surgical and Treatment Auxiliary Medical Services (Trial)" which establishes a unified pricing framework for surgical robots, energy equipment consumables, and remote surgery technologies across the country [1][3]. 2. **Provincial Implementation Timeline**: Historical data suggests that it typically takes between six months to a year for provinces to implement specific projects and pricing after the NHSA's announcement [2]. 3. **Benefits of Pricing Directory**: The establishment of a clear pricing directory is expected to facilitate the entry of innovative devices into hospitals and increase the sales volume of consumables [4]. 4. **Impact on Clinical Promotion**: Previously, the need for medical institutions to apply for self-pricing or provincial pricing led to reduced enthusiasm for clinical promotion. The new pricing directory aims to streamline the final pricing model across provinces, enhancing the accessibility of advanced medical technologies and promoting a shift from traditional to precision medicine [5]. 5. **Tiered Pricing System for Surgical Robots**: A tiered pricing system based on the clinical value and participation level of surgical robots has been introduced. Prices will be set in three tiers: navigation, participation in execution, and precise execution. The guidelines also include specific consumables in the pricing structure [5]. 6. **Independent Pricing for Remote Surgery**: Remote surgery has been given independent pricing status, which is expected to benefit leading hospitals and increase surgical volumes [6]. 7. **Clarification on Consumable Charges**: The guidelines clarify the charging logic for disposable and reusable consumables, stating that disposable consumables will be sold at zero markup, while reusable consumables will incur an auxiliary operation fee [7]. Key Beneficiaries 1. **MicroPort Robotics**: A leading domestic surgical robot company with over 160 cumulative orders for laparoscopic robots expected by December 2025. The company is positioned to capitalize on the commercialization of surgical robots and expand market share through innovative procedures [8]. 2. **JinFeng Medical**: Among the top two domestic surgical robot manufacturers, it is rapidly increasing the volume of multi-port and single-port laparoscopic robots, leading in domestic procurement bids [8]. 3. **Tianzhihang**: A leader in orthopedic surgical robots, the company has developed a comprehensive business model that includes equipment, consumables, and technical services [8]. 4. **Sanyou Medical**: Focused on developing three-arm spinal surgical robots and ultrasonic bone knives, benefiting from the new pricing regulations for energy equipment consumables [8]. 5. **Aikang Medical**: Set to launch a second-generation knee joint surgical robot in collaboration with Peking University Third Hospital, aiming to provide a complete digital orthopedic solution [8]. 6. **Chunli Medical**: Innovating with handheld robotic technology, the company plans to establish multiple surgical training centers overseas to accelerate international expansion [9].

Group 1 - The core viewpoint of the article highlights the recent trading activity of southbound funds in Spring Medical (01858.HK), indicating a mixed trend with both increases and decreases in holdings [1] - Southbound funds increased their holdings by 368,800 shares on January 19, while over the past five trading days, there were three days of net reductions totaling 505,000 shares [1] - Over the last 20 trading days, there were ten days of net reductions, amounting to a total of 2,725,500 shares [1] Group 2 - As of now, southbound funds hold 41,741,300 shares of Spring Medical, which represents 43.86% of the company's total issued ordinary shares [1] - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]